相关实验视频

Updated: Sep 16, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在现实实践中,新辅助免疫化学疗法与IB-IIIB非小细胞肺癌的老年患者的化疗相比,新辅助免疫化学疗法

Yongfeng Shuai¹, Jiacong Liu², Yuhong Yang²

¹Department of Plastic Surgery, the Second Hospital of Yinzhou, No. 998 Qianhe Road, Ningbo, 315000, China. shuaiyongfeng000@163.com.

|July 6, 2025

概括

与单独的化疗相比,新辅助免疫化疗显著改善了老年非小细胞肺癌患者的生存率和反应率. 治疗被发现是安全的,并没有显著增加不良事件.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
癌症治疗方法癌症治疗方法

背景情况:

没有驱动突变的非小细胞肺癌 (NSCLC) 的标准治疗方法是免疫化疗.
在患有NSCLC的老年患者 (≥65岁) 免疫化疗的有效性和安全性仍然不清楚.

研究的目的:

为了比较新辅助免疫化学疗法与化学疗法的安全性和有效性,在患有IB-IIIB期NSCLC的老年患者中进行化疗.

主要方法:

对140名接受新辅助免疫化学疗法或化疗的老年NSCLC患者 (IB-IIIB阶段) 的回顾性研究.
主要终点:无病生存率 (DFS) 和整体生存率 (OS).
二级终点:病理反应 (MPR,pCR),不良事件 (AE) 和客观反应率 (ORR).

主要成果:

与化疗相比,免疫化疗组显示DFS和OS显著改善.
免疫化疗组的客观响应率 (ORR) 在免疫化疗组 (73.1%对29.8%) 较高.
主要病理反应 (MPR) 率在免疫化学疗法 (64.4%对25.8%) 显着更高; 3-4级的副作用没有显著增加.

结论:

新辅助免疫化学疗法为老年NSCLC患者提供了改善的生存率,ORR和MPR率.
与单独的化疗相比,这种治疗在这个人群中显示出有利的安全性概况.

关键词:

化疗化疗是一种化学疗法.老年患者 (≥65岁) 患者免疫化疗是一种免疫化学疗法.新辅助治疗新辅助治疗非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...